Adamas Pharmaceuticals | Advantaged Therapeutics

	Contact \|

Overview Management Team Board of Directors Scientific & Clinical Advisors Investors Contact Us

Our Approach Programs Commercialization Partners

Publications & Presentations Reference Library

Press Releases Events

Culture Benefits Job Postings

TRINITY is setting the industry gold standard for oral delivery of macromolecules.

A New Model: Advantaged Therapeutics

	Dementia Read about ADS-8703
	Parkinson's Disease Read about ADS-5102
	Influenza Read about ADS-8901/2

News

Adamas' (TCAD)Therapy Is Well Tolerated In A Pilot Study Of Immunocompromised Patients With Influenza A (4/28/2010)

Adamas' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible And Resistant Strains Of Influenza In Animal Models (3/15/2010)

In Vitro Study of Adamas' Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses (9/13/2009)